Novo Nordisk

Foreign Filer Report • May 6, 2024

6-K 1 f6k_050324.htm FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____

FORM 6-K

____

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

May 3, 2024

____

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

____

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

Field: Page; Sequence: 1

Field: /Page

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 3 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

| a) | Details of the person discharging managerial responsibilities/person
closely associated — Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |
| --- | --- | --- | --- |
| 2 | Reason for the notification | | |
| a) | Position/status | Executive Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | | |
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | | |
| a) | Description of the financial instrument, | Shares | |
| | type of instrument, | | |
| | Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 900.05 | 178 shares |
| d) | Aggregated information | | |
| | · Aggregated volume | 178 shares | |
| | · Price | DKK 160,208.90 | |
| e) | Date of the transaction | 2024-05-02 | |
| f) | Place of the transaction | AQUIS EXCHANGE EUROPE AUCTION ON DEMAND (AOD) | |

Field: Page; Sequence: 2

Field: /Page

| a) | Details of the person discharging
managerial responsibilities/person closely associated — Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description of the financial instrument, | Shares | |
| | type of instrument, | | |
| | Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 900.74 | 10,128 shares |
| d) | Aggregated information | | |
| | · Aggregated volume | 10,128 shares | |
| | · Price | DKK 9,122,689.30 | |
| e) | Date of the transaction | 2024-05-02 | |
| f) | Place of the transaction | AQUIS EXCHANGE EUROPE NON DISPLAY ORDER BOOK (NDOB) | |

Field: Page; Sequence: 3

Field: /Page

| a) | Details of the person discharging
managerial responsibilities/person closely associated — Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description of the financial instrument, | Shares | |
| | type of instrument, | | |
| | Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 900.17 | 2,253 shares |
| d) | Aggregated information | | |
| | · Aggregated volume | 2,253 shares | |
| | · Price | DKK 2,028,089.70 | |
| e) | Date of the transaction | 2024-05-02 | |
| f) | Place of the transaction | AQUIS EXCHANGE EUROPE | |

Field: Page; Sequence: 4

Field: /Page

| a) | Details of the person discharging
managerial responsibilities/person closely associated — Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description of the financial instrument, | Shares | |
| | type of instrument, | | |
| | Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 900.10 | 18,153 shares |
| d) | Aggregated information | | |
| | · Aggregated volume | 18,153 shares | |
| | · Price | DKK 16,339,540.90 | |
| e) | Date of the transaction | 2024-05-02 | |
| f) | Place of the transaction | CBOE EUROPE - DXE ORDER BOOKS (NL) | |

Field: Page; Sequence: 5

Field: /Page

| a) | Details
of the person discharging managerial responsibilities/person closely associated — Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description of the financial instrument, | Shares | |
| | type of instrument, | | |
| | Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 900.14 | 2,800 shares |
| d) | Aggregated information | | |
| | · Aggregated volume | 2,800 shares | |
| | · Price | DKK 2,520,380.90 | |
| e) | Date of the transaction | 2024-05-02 | |
| f) | Place of the transaction | TURQUOISE EUROPE | |

Field: Page; Sequence: 6

Field: /Page

| a) | Details
of the person discharging managerial responsibilities/person closely associated — Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description of the financial instrument, | Shares | |
| | type of instrument, | | |
| | Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 900.00 | 10,437 shares |
| d) | Aggregated information | | |
| | · Aggregated volume | 10,437 shares | |
| | · Price | DKK 9,393,300.00 | |
| e) | Date of the transaction | 2024-05-02 | |
| f) | Place of the transaction | UBS EUROPE SE | |

Field: Page; Sequence: 7

Field: /Page

| a) | Details of the person discharging
managerial responsibilities/person closely associated — Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description of the financial instrument, | Shares | |
| | type of instrument, | | |
| | Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 912.15 | 11,051 shares |
| d) | Aggregated information | | |
| | · Aggregated volume | 11,051 shares | |
| | · Price | DKK 10,080,130.60 | |
| e) | Date of the transaction | 2024-05-02 | |
| f) | Place of the transaction | NASDAQ COPENHAGEN A/S | |

Field: Page; Sequence: 8

Field: /Page

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James- Brown +45 3079 9289 abmo@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com

Investors:
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com	Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com	Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com
Sina Meyer +45 3079 6656 azey@novonordisk.com

Novo Nordisk A/S Investor Relations
Company
announcement No 36 / 2024

Field: Page; Sequence: 9

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: May 3, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer

Field: Rule-Page

Field: /Rule-Page